Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
For partners & investors

A delivery platform built to de-risk genetic medicines

Why delivery matters commercially, where our programmes stand and the ways we work with pharma, biotech and investors.

Explore co-developmentDownload our capabilities deck
Programmes
8
IND-enabling or later
3
Co-development case studies
3
Market opportunity

Why delivery is where the value is

Nucleic acid medicines are proven

Approved siRNA, antisense and mRNA products have shown that genetic medicines work at scale. The next wave of programmes depends on getting them to new tissues.

Delivery is the bottleneck

Most approved lipid nanoparticle products act in the liver or are injected into muscle. Reaching tumours, the CNS or immune cells efficiently remains largely unsolved.

Escape efficiency is the lever

Only a few per cent of internalised cargo typically reaches the cytosol. Modest gains in escape can translate into lower doses, wider safety margins and lower cost of goods.

Pipeline milestones

Where the programmes stand

Full pipeline →
  1. 2019

    Company founded

    Spun out of the Cambridge Nanolab with seed backing and three founding scientists.

  2. 2021

    BrilliantCore™ validated

    First peer-reviewed demonstration of pH-tuned endosomal escape in vivo.

  3. 2023

    GMP suite opened

    Continuous-flow manufacturing line commissioned for clinical-scale supply.

  4. 2025

    First clinical readout

    BB-510 diagnostic panel entered clinical evaluation with a hospital network.

  5. 2026

    Two IND filings

    BB-101 and BB-207 progressing through IND-enabling toxicology.

  • BB-101 · Oncology

    IND-enabling

  • BB-114 · Oncology

    Preclinical

  • BB-207 · Vaccines

    IND-enabling

  • BB-233 · Immunology

    Lead opt.

  • BB-318 · Neurology

    Preclinical

  • BB-402 · Rare disease

    Lead opt.

  • BB-510 · Diagnostics

    Clinical

  • BB-604 · Diagnostics

    Preclinical

Partnership models

Four ways to work with us

8–12 weeks · fixed fee

Feasibility study

We formulate your payload in a focused carrier panel and report size, encapsulation, potency and tolerability against agreed criteria.

Milestone-based

Co-development

Joint programme from candidate selection to IND-enabling studies, with shared governance and milestone and royalty economics.

Field-limited

Technology licence

Licence to BrilliantCore™ lipids and process know-how for a defined payload, target or indication.

Clinical batches

GMP supply

Continuous-flow manufacturing and release testing for clinical material, with the same process used in development.

Case studies

Co-development in practice

All case studies →
Oncology

Moving an siRNA payload beyond the liver into solid tumours

A charge-shifting carrier that stays near-neutral in blood and becomes cationic in the acidic tumour microenvironment.

Vaccines

A self-amplifying RNA vaccine that tolerates refrigerator storage

Formulation and lyophilisation work that removed the need for frozen shipping in a low-resource setting.

Neurology

Making a CNS oligonucleotide programme measurable earlier

A biosensing readout that tracks oligonucleotide exposure in cerebrospinal fluid, so dose decisions no longer wait for tissue analysis.

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.

Prefer to talk it through? Book a 30-minute discovery call